Last Price
3.02
Today's Change
0.00 (0.00%)
Day's Change
2.77 - 3.07
Trading Volume
381,065
Overview
Market Cap
219 Million
Shares Outstanding
72 Million
Avg Volume
259,043
Avg Price (50 Days)
3.05
Avg Price (200 Days)
2.61
PE Ratio
-7.95
EPS
-0.38
Earnings Announcement
07-Nov-2024
Previous Close
3.02
Open
2.95
Day's Range
2.77 - 3.07
Year Range
0.97 - 4.0
Trading Volume
381,065
Price Change Highlight
1 Day Change
0.00%
5 Day Change
-4.13%
1 Month Change
2.37%
3 Month Change
17.05%
6 Month Change
-2.89%
Ytd Change
132.31%
1 Year Change
48.04%
3 Year Change
140.64%
5 Year Change
-30.45%
10 Year Change
-61.72%
Max Change
-61.72%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Latest Videos
Apps
Top Articles
1
CEO Morning Brief
2
3
4
CEO Morning Brief
US Services Activity Expands at Fastest Pace Since Early 2023
5
CEO Morning Brief
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
